ArticleMolecules (Basel, Switzerland)2019
Hyaluronic Acid Coated Acid-Sensitive Nanoparticles for Targeted Therapy of Adjuvant-Induced Arthritis in Rats.
Article in Molecules (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Acid-responsive nanoparticles with microneedles for anti‑inflammatory sonodynamic therapy of gouty arthritis.Drug delivery · 2026Article
- Therapeutic Efficacy of Dual-Targeting Nanoparticles with Low Immunogenicity in the Treatment of Rheumatoid Arthritis.Journal of functional biomaterials · 2026Article
- Synthesis, characterisation, andFrontiers in drug delivery · 2026Article
- Progress in Hyaluronan-Based Nanoencapsulation Systems for Smart Drug Release and Medical Applications.Molecules (Basel, Switzerland) · 2025Review
- Cationic Micelle-like Nanoparticles as the Carrier of Methotrexate for Glioblastoma Treatment.Molecules (Basel, Switzerland) · 2024Article
- Application of Nanomaterials Targeting Immune Cells in the Treatment of Chronic Inflammation.International journal of nanomedicine · 2024Review
- Nano - Based Therapeutic Strategies in Management of Rheumatoid Arthritis.Recent patents on nanotechnology · 2024Review
- Triterpenes Drug Delivery Systems, a Modern Approach for Arthritis Targeted Therapy.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Metabolic reprogramming of proinflammatory macrophages by target delivered roburic acid effectively ameliorates rheumatoid arthritis symptoms.Signal transduction and targeted therapy · 2023Article
- Design of Targeted Flurbiprofen Biomimetic Nanoparticles for Management of Arthritis: In Vitro and In Vivo Appraisal.Pharmaceutics · 2022Article
- Hyaluronic Acid: A Key Ingredient in the Therapy of Inflammation.Biomolecules · 2021Review
- Nanomedicines for the treatment of rheumatoid arthritis: State of art and potential therapeutic strategies.Acta pharmaceutica Sinica. B · 2021Review
- Modulation of Inflammatory Mediators by Polymeric Nanoparticles Loaded with Anti-Inflammatory Drugs.Pharmaceutics · 2021Article
- Nanomaterials Manipulate Macrophages for Rheumatoid Arthritis Treatment.Frontiers in pharmacology · 2021Review
- Stimuli-responsive polymeric nanomaterials for rheumatoid arthritis therapy.Biophysics reports · 2020Article
- Intraarticular Injection of Infliximab-Loaded Thermosensitive Hydrogel Alleviates Pain and Protects Cartilage in Rheumatoid Arthritis.Journal of pain research · 2020Article
- Hyaluronic acid-functionalized bilosomes for targeted delivery of tripterine to inflamed area with enhancive therapy on arthritis.Drug delivery · 2019Article
- Receptor targeting drug delivery strategies and prospects in the treatment of rheumatoid arthritis.Research in pharmaceutical sciences · 2019Review
- Hybrid micelles containing methotrexate-conjugated polymer and co-loaded with microRNA-124 for rheumatoid arthritis therapy.Theranostics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Activated macrophages play a vital role in rheumatoid arthritis (RA) pathophysiology. CD44 is an overexpressed receptor on activated macrophages that is a potential target site for RA treatment. In this study, we prepared hyaluronic acid (HA) coated acid-sensitive polymeric nanoparticles (HAPNPs) composed of egg phosphatidylcholine, polyethylenimine, and poly (cyclohexane-1,4-diyl acetone dimethylene ketal) (PCADK) loaded with dexamethasone (Dex) for the treatment of RA. PCADK was used to form polymeric cores because of its acid-sensitivity. The HAPNPs were about 150 nm in size and had a zeta potential of -2.84 mV. The release rate of Dex from HAPNPs/Dex in vitro increased markedly when the pH decreased from 7.4 to 4.5, indicating that the HAPNPs were pH-sensitive. In a cellular uptake study, stronger fluorescence signals were observed in activated macrophages treated with HAPNPs, suggesting that HAPNPs could be effective nanodevices target to activated macrophages. In rats with adjuvant-induced arthritis, HAPNPs could inhibited the progression of RA. Taken together, these results suggest that the HAPNPs could be useful in RA therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.